QR-koodi

Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study

<b>Background</b>: Higher-risk myelodysplastic neoplasms (HR-MDS) are associated with poor survival and a substantial risk of leukemic transformation. Although azacitidine is a standard treatment in this setting, comparative real-world data remain limited. We evaluated the association between azacit...

Täydet tiedot

Tallennettuna:
Päätekijät: Mihai-Emilian Lapadat, Oana Stanca, Irina Nicoleta Triantafyllidis, Anca Mariana Ciobanu, Nicoleta Mariana Berbec, Cristina Negotei, Cristian Tudor Barta, Ana Maria Bordea, Madalina Marilena Oprea, Andrei Colita
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2026-04-01
Sarja:Medical Sciences
Aiheet:
higher-risk myelodysplastic neoplasms
azacitidine
hypomethylating agents
overall survival
leukemic transformation
IPSS-R
Linkit:https://www.mdpi.com/2076-3271/14/2/212
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia